Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Naproxen Sodium Codeine
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, NAPROXEN SODIUM
Eligibility Criteria
Inclusion Criteria:
- Clinical and radiological diagnosis of primary osteoarthritis (knee and hip) in the recent year according to criteria of American College of Rheumatology (ACR)
- Grade 1, 2 or 3 osteoarthritis patients
- Patients 40 to 65 years of age
- Patients with WOMAC score ≥ 40
- Patients with VAS score ≥ 40
- Patients who signed the consent form
Exclusion Criteria:
- Grade 4 osteoarthritis patients / Pregnant or breastfeeding mothers
- Patients with known allergic reaction or intolerance to NSAIDs (nonsteroidal antiinflammatory drugs)
- Patients hypersensitive to naproxen sodium or codeine
- Patients who took another analgesic medicine during 24 hours before and/or a nonsteroidal anti-inflammatory medicine during 72 hours before taking study medicine
- Patients with active gastric or duodenum ulcer
- Patients with renal dysfunction and/or a kidney disease
- Patients with severe liver disease
- Patients with rare hereditary galactose intolerance, Lapp lactase insufficiency or glucose-galactose malabsorption problem
- Patients with depression treated by a medicine from monoamine oxidase class
- Patients with uncontrolled hypertension or patients with hypertension that is hardly controlled with medicines
- Patients with a known medical, psychological disturbance or social status that may negatively affect inclusion into the study or patients who may lead to increase in risk for others with inclusion into the study
- Patients with proven clinically important and unstable systemic medical disease
- Patients who have medical contraindication for study medicine
- Patients who are judged by investigator that they will not adhere or adequately adhere to the study protocol
- Patients who participated into another study with another study medicine in the last 4 week
- Patients who intent to donate blood or blood product during the study period or in the following month of the study completion
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Naproxen Sodium Codeine
Placebo
Arm Description
One tablet twice a day
One tablet twice a day
Outcomes
Primary Outcome Measures
Change in Western Ontario Mac Master Questionnaire (WOMAC)
Change in Visual Analog Scale (VAS)
Secondary Outcome Measures
Change in pain severity in all visits after treatment from baseline (VAS)
Functional effects of combination therapy (WOMAC)
Change in resting pain after treatment from baseline (WOMAC)
Change in activity pain after treatment from baseline (WOMAC)
Change in physical function after treatment from baseline (WOMAC)
Ratio of rescue medicine use (Rescue medication count)
Collection of adverse event reports to evaluate safety of the medicine
Full Information
NCT ID
NCT02501564
First Posted
July 9, 2015
Last Updated
February 24, 2016
Sponsor
Istanbul Medeniyet University
Collaborators
Abdi Ibrahim Ilac San. ve Tic A.S.
1. Study Identification
Unique Protocol Identification Number
NCT02501564
Brief Title
Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
Official Title
Randomized, Double-blind and Placebo-controlled Evaluation of Efficacy and Safety of Naproxen Sodium and Codeine Phosphate Combination in Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istanbul Medeniyet University
Collaborators
Abdi Ibrahim Ilac San. ve Tic A.S.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Osteoarthritis (OA) pain treatment has limitations in terms of serious adverse effects and low efficacy. The investigators aimed to evaluate efficacy and safety of naproxen sodium/codeine phosphate combination in these patients.
Detailed Description
In this prospective, randomized, double blind, placebo controlled clinical trial, 135 patients with osteoarthritis, who were 40-65 years; applied to institution's orthopaedics outpatient clinic; had grade 1, 2, or 3 primary osteoarthritis diagnosed in last 1 year; and had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score≥40, and Visual Analogue Scale score≥40,were enrolled. Subjects were randomized (1:1) to placebo (n= 67) or combination (n= 68) arms, in which 550 mg naproxen sodium/30mg codeine phosphate was given orally twice a day for 7 days. Rescue medicine was 500 mg paracetamol (max= 6 tablets/day). Demographic characteristics, medical history, adverse events, VAS and WOMAC scores were collected in study visits performed within 10days.The study was approved by local institutional ethics committee and written informed consents were obtained from all participants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteoarthritis, NAPROXEN SODIUM
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
135 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Naproxen Sodium Codeine
Arm Type
Experimental
Arm Description
One tablet twice a day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
One tablet twice a day
Intervention Type
Drug
Intervention Name(s)
Naproxen Sodium Codeine
Other Intervention Name(s)
Apranax Plus
Intervention Description
One tablet twice a day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
One tablet twice a day
Primary Outcome Measure Information:
Title
Change in Western Ontario Mac Master Questionnaire (WOMAC)
Time Frame
7 days
Title
Change in Visual Analog Scale (VAS)
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Change in pain severity in all visits after treatment from baseline (VAS)
Time Frame
7 days
Title
Functional effects of combination therapy (WOMAC)
Time Frame
7 days
Title
Change in resting pain after treatment from baseline (WOMAC)
Time Frame
7 days
Title
Change in activity pain after treatment from baseline (WOMAC)
Time Frame
7 days
Title
Change in physical function after treatment from baseline (WOMAC)
Time Frame
7 days
Title
Ratio of rescue medicine use (Rescue medication count)
Time Frame
7 days
Title
Collection of adverse event reports to evaluate safety of the medicine
Time Frame
7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical and radiological diagnosis of primary osteoarthritis (knee and hip) in the recent year according to criteria of American College of Rheumatology (ACR)
Grade 1, 2 or 3 osteoarthritis patients
Patients 40 to 65 years of age
Patients with WOMAC score ≥ 40
Patients with VAS score ≥ 40
Patients who signed the consent form
Exclusion Criteria:
Grade 4 osteoarthritis patients / Pregnant or breastfeeding mothers
Patients with known allergic reaction or intolerance to NSAIDs (nonsteroidal antiinflammatory drugs)
Patients hypersensitive to naproxen sodium or codeine
Patients who took another analgesic medicine during 24 hours before and/or a nonsteroidal anti-inflammatory medicine during 72 hours before taking study medicine
Patients with active gastric or duodenum ulcer
Patients with renal dysfunction and/or a kidney disease
Patients with severe liver disease
Patients with rare hereditary galactose intolerance, Lapp lactase insufficiency or glucose-galactose malabsorption problem
Patients with depression treated by a medicine from monoamine oxidase class
Patients with uncontrolled hypertension or patients with hypertension that is hardly controlled with medicines
Patients with a known medical, psychological disturbance or social status that may negatively affect inclusion into the study or patients who may lead to increase in risk for others with inclusion into the study
Patients with proven clinically important and unstable systemic medical disease
Patients who have medical contraindication for study medicine
Patients who are judged by investigator that they will not adhere or adequately adhere to the study protocol
Patients who participated into another study with another study medicine in the last 4 week
Patients who intent to donate blood or blood product during the study period or in the following month of the study completion
12. IPD Sharing Statement
Learn more about this trial
Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
We'll reach out to this number within 24 hrs